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abstract
background
From the City of Hope National Medical
Center, Duarte, Calif. (R.S.); Loyola University Medical Center, Maywood, Ill. (P.S.);
the Fred Hutchinson Cancer Research Center, Seattle (W.B.); State University of New
York Upstate Medical University, Syracuse
(T.G.); the University of Minnesota, Minneapolis (D.W., B.R.B.); Memorial SloanKettering Cancer Center, New York (T.K.);
the University of North Carolina, Chapel
Hill (T.S.); Georgetown University Cancer
Center, Washington, D.C. (S.Y.); the Northwest Marrow Transplant Center, Portland,
Oreg. (K.H.); Sinai Hospital of Baltimore,
Baltimore (S.N.); the Medical College of
Virginia, Richmond (J.M.); the Texas Transplant Institute, San Antonio (C.F.L.); the
School of Dentistry (E.C.S.) and the Division of Hematology/Oncology (C.E.), University of California at Los Angeles, Los
Angeles; and Amgen, Thousand Oaks, Calif. (D.E., M.-G.C.). Address reprint requests
to Dr. Spielberger at the City of Hope National Medical Center, Department of Hematology and Hematopoietic Cell Transplantation and Kaiser Permanente BMT
Program, 1500 E. Duarte Rd., Duarte, CA
91010, or at rspielberger@coh.org.
N Engl J Med 2004;351:2590-8.
Copyright © 2004 Massachusetts Medical Society.

Oral mucositis is a complication of intensive chemotherapy and radiotherapy with no effective treatment. We tested the ability of palifermin (recombinant human keratinocyte
growth factor) to decrease oral mucosal injury induced by cytotoxic therapy.
methods

This double-blind study compared the effect of palifermin with that of a placebo on the
development of oral mucositis in 212 patients with hematologic cancers; 106 patients
received palifermin (60 µg per kilogram of body weight per day) and 106 received a placebo intravenously for three consecutive days immediately before the initiation of conditioning therapy (fractionated total-body irradiation plus high-dose chemotherapy) and
after autologous hematopoietic stem-cell transplantation. Oral mucositis was evaluated
daily for 28 days after transplantation.
results

The incidence of oral mucositis of World Health Organization (WHO) grade 3 or 4 was
63 percent in the palifermin group and 98 percent in the placebo group (P<0.001).
Among patients with this degree of mucositis, the median duration of mucositis was
6 days (range, 1 to 22) in the palifermin group and 9 days (range, 1 to 27) in the placebo
group. Among all patients, regardless of the occurrence of mucositis, the median duration of oral mucositis of WHO grade 3 or 4 was 3 days (range, 0 to 22) in the palifermin
group and 9 days (range, 0 to 27) in the placebo group (P<0.001). As compared with
placebo, palifermin was associated with significant reductions in the incidence of
grade 4 oral mucositis (20 percent vs. 62 percent, P<0.001), patient-reported soreness
of the mouth and throat (area-under-the-curve score, 29.0 [range, 0 to 98] vs. 46.8
[range, 0 to 110]; P<0.001), the use of opioid analgesics (median, 212 mg of morphine
equivalents [range, 0 to 9418] vs. 535 mg of morphine equivalents [range, 0 to 9418],
P<0.001), and the incidence of use of total parenteral nutrition (31 percent vs. 55 percent, P<0.001). Adverse events, mainly rash, pruritus, erythema, mouth and tongue disorders, and taste alteration, were mild to moderate in severity and were transient.
conclusions

Palifermin reduced the duration and severity of oral mucositis after intensive chemotherapy and radiotherapy for hematologic cancers.
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h

igh-dose chemotherapy and radiotherapy followed by hematopoietic
stem-cell support is a well-established
treatment for hematologic cancers. Oral mucositis
develops and requires treatment in approximately
70 to 80 percent of patients receiving radiationbased conditioning treatments.1,2 The incidence
and severity of oral mucositis vary with the conditioning regimen.
Oral mucositis results from injury to epithelial
cells that line the oral cavity. The damage causes
changes ranging from mild atrophy to severe ulceration. Serious consequences include pain requiring
opioid analgesia, potentially life-threatening infections, inadequate nutrition requiring parenteral
feeding, and prolonged hospitalization.1-5 Currently, no standard therapy prevents or treats severe oral
mucositis.6,7
Keratinocyte growth factor is a 28-kD, heparinbinding member of the family of fibroblast growth
factors that was originally isolated from pulmonary
fibroblasts as a protein (FGF-7) with keratinocytestimulating activity. Palifermin (recombinant human keratinocyte growth factor) is an N-terminal,
truncated version of endogenous keratinocyte
growth factor with biologic activity similar to that
of the native protein, but with increased stability.8
In animal models of chemotherapy, radiotherapy,
and hematopoietic stem-cell transplantation,9,10
palifermin protected several types of epithelial tissues. A phase 1 trial indicated that palifermin at
doses of up to 80 µg per kilogram of body weight
per day for three consecutive days was not associated with major adverse events.11 We evaluated the
efficacy and safety of palifermin in reducing the duration and severity of oral mucositis and its sequelae
(soreness of the mouth and throat, use of opioid analgesics and total parenteral nutrition, and infections) in patients with hematologic cancers who
were undergoing autologous hematopoietic stemcell transplantation after receiving total-body irradiation and high-dose chemotherapy.

methods
patients

The institutional review board at each of the 13 study
sites approved the study protocol; all patients gave
written informed consent before all study-related
procedures. This study enrolled patients who were
at least 18 years of age, had a Karnofsky performance-status score of at least 70, and were sched-

n engl j med 351;25

uled to undergo autologous stem-cell transplantation after receiving a conditioning regimen12-15 of
fractionated total-body irradiation plus etoposide
and cyclophosphamide for non-Hodgkin’s lymphoma, Hodgkin’s disease, acute myelogenous leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, or multiple myeloma. Patients
were to have at least 1.5¬106 cryopreserved CD34+
cells per kilogram available for transplantation and
adequate cardiac, pulmonary, renal, and hepatic
function, as determined by institutional guidelines.
study drug

Palifermin and its matching placebo were manufactured and packaged by Amgen. The placebo contained all the ingredients of the palifermin preparation (i.e., 10 mM histidine [pH 6.5], 2 percent
sucrose, 4 percent mannitol, and 0.01 percent
polysorbate 20) except palifermin.
study design

In this placebo-controlled, double-blind, phase 3
trial, patients were randomly assigned in a 1:1 ratio
(stratified according to center and type of hematologic cancer) to receive palifermin (60 µg per kilogram per day) or placebo intravenously for three
consecutive days, starting three days before the initiation of total-body irradiation. After the conditioning regimen was administered, patients received
three additional doses16 of palifermin or placebo on
days 0, 1, and 2 after transplantation. Filgrastim
(Neupogen, Amgen) (5 µg per kilogram per day)
was administered to all patients daily from the day
of transplantation until the neutrophil count recovered.
Conditioning therapy and supportive care were
administered according to standard institutional
practice. Total-body irradiation (total, 1200 cGy)
was delivered in 6, 8, or 10 fractions over a period
of three or four days, with at least six hours between fractions, before chemotherapy was administered. Chemotherapy included intravenous etoposide (60 mg per kilogram) the day after the last
radiation fraction (four days before transplantation)
and one dose of cyclophosphamide (100 mg per kilogram) two days before transplantation. Patients
received peripheral-blood hematopoietic stem cells
collected after mobilization by means of either cytokines or chemotherapy with or (for one patient)
without cytokines.
Oral mucositis was assessed with the use of three
scales: the five-grade World Health Organization
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(WHO) oral-toxicity scale17 (primary scale), the fivegrade Radiation Therapy Oncology Group (RTOG)
acute radiation–morbidity scoring criteria for mucous membranes,18 and the four-grade Western
Consortium for Cancer Nursing Research (WCCNR)
revised staging system for oral mucositis.19 At each
center, Clinical Assistance Programs trained evaluation-team members to assess and document oral
mucositis. Each patient was assessed daily for oral
mucositis beginning 8 days before transplantation
and continuing for 28 days after transplantation or
until severe oral mucositis had resolved (i.e., returned to WHO grade 0, 1, or 2).
Data on patient-reported outcomes (soreness of
the mouth and throat and ability to participate in
the activities of daily living) were collected with the
use of a daily questionnaire. The functional and
physical well-being domains of the Functional Assessment of Cancer Therapy general questionnaire20 were collected daily from 12 days before
transplantation to 28 days after transplantation
(total, 41 days).
Information concerning the use of parenteral or
Table 1. Baseline Characteristics of the Patients.

Characteristic
Male sex — no. (%)

Palifermin
Group
(N=106)

Placebo
Group
(N=106)

59 (56)

72 (68)

Age — yr
Median

48

49

Range

18–69

19–68

Non-Hodgkin’s lymphoma

72 (68)

69 (65)

Hodgkin’s disease

21 (20)

23 (22)

Multiple myeloma

11 (10)

9 (8)

2 (2)

5 (5)

Diagnosis — no. (%)

Leukemia*
Karnofsky performance-status score — no. (%)
70

3 (3)

1 (1)

80

15 (14)

19 (18)

90

59 (56)

58 (55)

100

29 (27)

28 (26)

Total no. of CD34+ cells reinfused —

¬10¡6/kg

Median

5.2

5.0

Range

1.8–87.0

1.5–41.0

* This category includes acute lymphoblastic leukemia (one patient in the palifermin group), acute myelogenous leukemia (one patient in the palifermin group
and four in the placebo group), and chronic lymphocytic leukemia (one patient
in the placebo group) in complete remission.
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transdermal narcotic analgesics was collected daily.
Total parenteral nutrition was given according to
the standards of each study site.
Antibodies against palifermin were assayed by
an electrochemiluminescence-based immunoassay
(IGEN International). Any positive test was followed by retesting for neutralizing antibodies with
a cell-based assay. Laboratory assessments included
routine hematologic and blood chemical tests and
measurement of serum amylase and lipase concentrations.
The study was designed by Amgen and the principal investigators, who also recruited the patients
and collected the data. The investigators and Ms.
Chen and Dr. Elhardt of Amgen analyzed the data;
all investigators had access to the data. The decision
to publish was made by the investigators and Amgen; no limitations were imposed by the sponsor.
The lead investigator wrote the article with editorial assistance from Amgen.
efficacy and safety end points

Analyses of all efficacy and safety end points included all patients who underwent randomization
and received at least one dose of study medication.
The prespecified primary end point was the duration of oral mucositis of WHO grade 3 (inability to
swallow solid food) or 4 (no form of oral alimentation possible); the duration was considered to be
zero days among patients who did not have oral
mucositis.
Other end points included the incidence of oral
mucositis of WHO grade 3 or 4, the duration of oral
mucositis of WHO grade 3 or 4 among patients with
this adverse effect, the incidence of WHO grade 4
oral mucositis, the duration of WHO grade 4 oral
mucositis among patients with this adverse effect,
the duration of oral mucositis of WHO grade 2
(moderate) or higher, the duration of oral mucositis of RTOG grade 3 or 4, the duration of lesions
of WCCNR grade 2 or 3, the area under the curve
(AUC) for patient-reported outcomes of soreness of
the mouth and throat and swallowing limitations
plotted against time, scores for the Functional Assessment of Cancer Therapy general questionnaire,
and the total dose and duration of parenteral or
transdermal opioid analgesics. Additional exploratory end points included the incidence of febrile
neutropenia, the incidence of infections, and the incidence of the use of total parenteral nutrition.
Safety was assessed on the basis of the incidence of adverse events, graded on a five-point scale
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(a score of 1 indicates mild adverse effects, and a
score of 5 fatal adverse effects); changes in clinical
laboratory values; the occurrence of antibodies
against palifermin; and the rates of progression-free
survival and secondary cancers during follow-up.

similar in the two groups. A combination of chemotherapy and cytokines was used for CD34+ cell mobilization in 75 percent of patients in the palifermin
group and 72 percent of patients in the placebo
group. Most patients (92 percent of those in the palifermin group and 93 percent of those in the placebo
statistical analysis
group) received acyclovir or a similar antiviral drug.
The planned sample size of 210 patients (105 per Similar numbers of patients in both groups comgroup) was chosen to provide the study with the sta- pleted the study: 103 patients in the palifermin
tistical power to detect a minimal mean (±SD) difference between groups in the duration of severe
oral mucositis of more than 3.0 ± 6.6 days, with the
Table 2. Effect of Palifermin on Oral Mucositis of WHO Grade 3 or 4
use of a t-test with 90 percent power and a two-sided
and Patient-Reported Outcomes.
significance level of 5 percent. For the end points inPalifermin
Placebo
volving the duration of oral mucositis, missing data
Group
Group
with two adjacent observed assessments were asVariable
(N=106)
(N=106)
P Value*
signed the poorer of the two adjacent values. For
Oral mucositis of WHO grade 3 or 4
each patient whose oral mucositis had not resolved
Incidence — no. of patients (%)†
67 (63)
104 (98)
<0.001
by the end of the study we imputed the duration by
Duration — days
assigning the mean duration among all patients
All patients
<0.001
who had severe oral mucositis for as long as or longMedian
3.0
9.0
er than the patient had it before the study ended.
Range
0–22
0–27
Treatment groups were compared by means of the
Patients with oral mucositis of
<0.001
generalized Cochran–Mantel–Haenszel method
WHO grade 3 or 4
stratified according to study center.21 The test staMedian
6.0
9.0
tistic was based on the within-stratum standardized
Range
1–22
1–27
midranks. Secondary end points were evaluated in
Patient-reported outcomes (AUC)‡
a prespecified order only after the primary end point
Score for soreness of mouth and throat
<0.001
was determined to be statistically significant. All
statistical tests were two-sided at the 0.05 level of
Median
29.0
46.8
significance. The Kaplan–Meier method22 was used
Range
0–98
0–110
to estimate the rate of progression-free survival.
Swallowing-limitation score
<0.001

results

Median

22.5

38.3

Range

0–104

0–104

Functional Assessment of Cancer
Therapy general score

patients

Between March 23, 2001, and October 23, 2002, 245
patients were screened, 214 (107 per group) were
randomly assigned to a treatment group, and 212
(106 per group) received at least one dose of palifermin or placebo and were included in the safety
and efficacy analyses. The center that enrolled the
most patients enrolled 19 percent of them.
The baseline characteristics of the patients were
similar in the two groups (Table 1). Of the 212 patients, 88 (83 percent) in the palifermin group and
86 (81 percent) in the placebo group had a baseline
Karnofsky performance-status score of at least 90.
All patients had received prior chemotherapy; 88
percent of those in the palifermin group and 92 percent of those in the placebo group had received no
prior radiotherapy. Radiotherapy schedules were

n engl j med 351;25

Physical well-being domain
Median

736.6

712.1

Range

176–1033

176–1014

Median

546.1

542.5

Range

93–985

93–1043

0.003

Functional well-being domain
0.036

* P values were calculated with the use of the generalized Cochran–Mantel–
Haenszel test stratified according to study center.
† P<0.001 for the two-part statistical model, which simultaneously considered
the incidence of oral mucositis of WHO grade 3 or 4 and the duration of oral
mucositis of WHO grade 3 or 4 among patients with this adverse effect.
‡ AUC denotes area under the curve of outcome plotted against time. A Likert
scale was used. For Functional Assessment of Cancer Therapy general score,
higher scores indicate a more favorable response (range of possible scores,
0 to 4), whereas higher scores for soreness of the mouth and throat and swallowing limitations indicate a worse response (range of possible scores, 0 to 4).
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A
Center
Number
45

(9.3 days; n=11)

44

(4.9 days; n=17)

43

(5.0 days; n=17)

41

(5.0 days; n=5)

40

(3.8 days; n=6)

38

(7.0 days; n=25)

37

(7.8 days; n=10)

36

(9.0 days; n=8)

34

(8.1 days; n=13)

33

(5.4 days; n=30)

32

(6.8 days; n=40)

31

(8.2 days; n=29)
¡10

¡5

0

5

10

15

20
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medicine

Figure 1. Mean Difference between the Placebo Group
and the Palifermin Group in the Duration of Mucositis
of WHO Grade 3 or 4, According to Center (Panel A),
Type of Hematologic Cancer (Panel B), and Number
of Fractions of Total-Body Irradiation (Panel C).
Values in parentheses are the mean differences in duration between the placebo group and the palifermin group
(also indicated by the squares) and the numbers of patients. Horizontal bars represent 95 percent confidence
intervals. The mean difference could not be calculated
for center 39, which enrolled only one patient, who received palifermin; centers 35, 42, and 46 did not enroll
any patients. The lower limit of the 95 percent confidence
interval for the difference in duration exceeded 0 days for
all centers except center 40 (six patients [four in the palifermin group and two in the placebo group]), for all hematologic cancers except leukemia (seven patients [two
and five, respectively]), and for all three irradiation subgroups.

Mean Difference in Duration
of Oral Mucositis (days)

B
Type of Hematologic
Cancer
Leukemia

(4.3 days; n=7)

Multiple
myeloma

(6.7 days; n=20)

Non-Hodgkin’s (6.9 days; n=141)
lymphoma
Hodgkin’s
disease

(6.5 days; n=44)
¡10

¡5

0

5

10

15

20

Mean Difference in Duration
of Oral Mucositis (days)

C
No. of Fractions
of Irradiation
10

(6.8 days; n=40)

8

(6.7 days; n=167)

6

(5.0 days; n=5)
¡10

¡5

0

5

10

15

20

Mean Difference in Duration
of Oral Mucositis (days)

group (97 percent) and 102 patients in the placebo
group (96 percent).
efficacy

Oral mucositis of WHO grade 3 or 4 developed in
67 of 106 patients in the palifermin group (63 percent) and 104 of 106 patients in the placebo group
(98 percent, P<0.001) (Table 2). The median dura-
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tion of oral mucositis of grade 3 or 4 among patients with this adverse effect was 6.0 days (range,
1 to 22) in the palifermin group and 9.0 days (range,
1 to 27) in the placebo group (P<0.001) (Table 2).
The median duration of oral mucositis of WHO
grade 3 or 4 among all patients was 3.0 days (range,
0 to 22) in the palifermin group and 9.0 days (range,
0 to 27) in the placebo group (P<0.001) (Table 2).
This result — the primary end point — was reproducible when the analysis was performed according
to center, type of hematologic cancer, or number of
fractions of irradiation (Fig. 1). A two-part statistical model,23 which simultaneously considered the
incidence of oral mucositis of WHO grade 3 or 4 and
the duration of oral mucositis of WHO grade 3 or
4 among patients with this adverse effect, showed
significant improvements in the palifermin group,
as compared with the placebo group (P<0.001) (Table 2).
The incidence of oral mucositis of WHO grade 4
(Fig. 2) was significantly lower among palifermin
recipients than among placebo recipients (20 percent vs. 62 percent, P<0.001), and the median duration of grade 4 oral mucositis was significantly
shorter among the 21 palifermin recipients than
among the 66 placebo recipients with this adverse
effect (2.0 days [range, 1 to 9] vs. 6.0 days [range,
1 to 37], P=0.004).
Approximately 3 percent of assessments for oral
mucositis were missing. In a sensitivity analysis that
imputed missing oral-mucositis assessments by assigning the worst possible score for palifermin and
the best possible score for placebo, the median du-
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Grade 0

A

Grade 0

3.5

Grade 1
Grade 2

80

Grade 2

3.0
Grade 3

Mean WHO Grade
of Oral Mucositis

Incidence of Oral Mucositis (%)

100

60

40

Grade 3
Grade 4

2.0
1.5
1.0

Palifermin

0.5

20

0.0
¡8

Grade 4
0

Placebo

2.5

0

7

14

21

28

103
105

103
104

102
100

21

28

96
97

79
85

Study Day
Palifermin
(n=106)

Placebo
(n=106)

No. Assessed
Placebo
Palifermin

Figure 2. Incidence of Oral Mucositis in the Palifermin
and Placebo Groups.

106
106

105
106

105
106

B
3.5

Mean Score for Mouth
and Throat Soreness

The severity of oral mucositis, as measured by the WHO
assessment scale, is classified as follows: no oral mucositis (grade 0); soreness or erythema (grade 1); erythema and ulcers (grade 2); extensive erythema, ulcers, and
inability to swallow solid food (grade 3); and mucositis
that prevents any form of alimentation, including swallowing liquids (grade 4). No patient in the placebo group
had grade 1 oral mucositis. The incidence of oral mucositis of WHO grade 3 or 4 was significantly lower in the
palifermin group than in the placebo group (P<0.001),
as was the incidence of grade 4 oral mucositis (P<0.001)
and the incidence of oral mucositis of grade 2 or higher
(P<0.01).

3.0
Placebo

2.5
2.0
1.5
1.0

Palifermin

0.5
0.0
¡8

0

7

14

Study Day
No. Assessed
Placebo
Palifermin

ration of oral mucositis of grade 3 or 4 was still significantly shorter in the palifermin group than in the
placebo group (3.0 days [range, 0 to 20] vs. 8.0 days
[range, 0 to 27], P<0.001).
Similar results were seen for other measurements of oral mucositis among all patients, including the median duration of oral mucositis of WHO
grade 2 or higher (8.0 days [range, 0 to 28] in the
palifermin group and 14.3 days [range, 0 to 37] in
the placebo group, P<0.001), the median duration of oral mucositis of RTOG grade 3 or 4 (0.0
days [range, 0 to 24] and 6.0 days [range, 0 to 54],
P<0.001), and the median duration of lesions of
WCCNR grade 2 or 3 (1.0 day [range, 0 to 36] and
7.0 days [range, 0 to 56], P<0.001).
In agreement with the measurement of oral mucositis, the median scores for the soreness of the
mouth and throat, measured by means of a Likert
(categorical) scale, were significantly lower in the
palifermin group than the placebo group (AUC,
29.0 [range, 0 to 98] vs. 46.8 [range, 0 to 110]; dif-

n engl j med 351;25

106
105

103
105

101
103

99
99

Figure 3. Mean WHO Grade of Oral Mucositis (Panel A) and Scores for Soreness of the Mouth and Throat (Panel B) during the Study.
The WHO grades were determined by members of the evaluation team, and
the scores for soreness of the mouth and throat were determined by the patients. For days ¡8 (before stem-cell transplantation), 0, 7, 14, 21, and 28, vertical lines represent 95 percent confidence intervals. Mouth soreness was
graded on a four-point scale, with higher scores indicating greater soreness.

ference between groups, 38 percent; P<0.001) (Table 2). By comparing daily mean scores for soreness
of the mouth and throat with the WHO grade of oral
mucositis, we found that the changes in the patientreported scores for soreness of the mouth and
throat preceded the observer-reported changes in
the grade of oral mucositis (Fig. 3). Similar results
were observed for the incidence and duration of
swallowing limitations (Table 2) and other patientreported sequelae related to soreness of the mouth
and throat (e.g., ability to drink, eat, talk, and sleep)
(data not shown). Palifermin recipients had signif-
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Table 3. Adverse Events Occurring with an Incidence That Was at Least
5 Percentage Points Higher in the Palifermin Group Than in the Placebo Group.

Type of Adverse Event

Palifermin
Group
(N=106)

Placebo
Group
(N=106)

no. of patients (%)
Rash

58 (55)

49 (46)

Pruritus

53 (50)

34 (32)

Erythema

47 (44)

32 (30)

Cough

34 (32)

28 (26)

Edema

29 (27)

18 (17)

Taste alteration

23 (22)

10 (9)

White film coating mouth or tongue

19 (18)

11 (10)

Rhinitis

17 (16)

9 (8)

Arthralgia

14 (13)

7 (7)

Sensation of increased tongue thickness

13 (12)

6 (6)

Perianal pain

12 (11)

5 (5)

Numbness (generally of 1 body area, including
the feet, fingers, and perioral area)

11 (10)

4 (4)

Taste loss

11 (10)

4 (4)

Paresthesia

10 (9)

1 (1)

icantly higher scores for the physical and functional
well-being domains of the Functional Assessment
of Cancer Therapy general questionnaire than did
placebo recipients, also indicating greater improvement (Table 2).
Palifermin recipients used less parenteral or
transdermal opioid analgesics for mucositis than
did placebo recipients, as measured by the median
cumulative dose administered (212 mg of morphine
equivalents [range, 0 to 9418] vs. 535 mg of morphine equivalents [range, 0 to 9418], P<0.001) and
the median duration of administration (7.0 days
[range, 0 to 28] vs. 11.0 days [range, 0 to 32],
P<0.001). Palifermin recipients had a lower incidence of febrile neutropenia than did placebo recipients (75 percent vs. 92 percent, P<0.001). Exploratory analysis revealed a trend toward a lower
incidence of blood-borne infections in the palifermin group than in the placebo group (15 percent vs.
25 percent). The incidence of the use of total parenteral nutrition during the study was also lower
among palifermin recipients than among placebo
recipients (31 percent vs. 55 percent, P<0.001).
safety

The incidence, frequency, and severity of adverse
events were similar in the two groups, and most
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were attributable to the underlying cancer, cytotoxic
chemotherapy, or total-body irradiation. Those that
occurred with an incidence that was at least 5 percentage points higher in the palifermin group than
in the placebo group are listed in Table 3. Most of
these adverse events were consistent with the pharmacologic action of palifermin on skin and oral epithelium (e.g., rash, pruritus, erythema, paresthesia,
mouth and tongue disorders, and taste alteration).
All these events were mild to moderate in severity,
transient (occurring approximately three days after
the third dose of palifermin and lasting approximately three days), and not a cause for the discontinuation of study drug.
Serious adverse events considered to be related
to treatment occurred in one palifermin recipient
(rash) and one placebo recipient (hypotension). Two
patients died during the study or within 30 days after the last dose of palifermin or placebo: one patient in the palifermin group died of veno-occlusive
liver disease, and one patient in the placebo group
died of sepsis. Neither death was considered to be
related to treatment.
Data collection on hematologic recovery after
transplantation was not prospectively specified;
however, by day 12 after transplantation, most palifermin recipients (90 percent) and placebo recipients (93 percent) had absolute neutrophil counts of
at least 500 per cubic millimeter.
Transient, asymptomatic increases in serum amylase (primarily of salivary origin) and lipase concentrations were observed in both groups, with the
peak value for amylase occurring on the last day of
irradiation and the peak value for lipase occurring
after the third dose of study drug. The increases
were higher in the palifermin group (median maximal increases from baseline, 166.5 U of amylase
per liter and 17.5 U of lipase per liter) than the placebo group (92.0 and 12.5 U per liter, respectively).
No additional increase was observed for either enzyme, and concentrations returned to near-baseline
values by the day of transplantation.
No clinically significant differences were observed between groups in other laboratory results.
Increases from baseline in WHO toxicity grades of
alanine aminotransferase, aspartate aminotransferase, bilirubin, alkaline phosphatase, and creatinine
concentrations — primarily one-grade increases —
were observed in less than 35 percent of patients in
each group. Antibodies against palifermin were not
detectable in any patient.
As of November 2003, the median duration of
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follow-up was 12.6 months in the palifermin group
and 12.0 months in the placebo group. The Kaplan–
Meier estimate of the rate of progression-free survival at 12 months was 0.69 (95 percent confidence
interval, 0.60 to 0.78) in the palifermin group and
0.73 (95 percent confidence interval, 0.64 to 0.82)
in the placebo group. In follow-up studies to date,
secondary cancers have been diagnosed in three patients: myelodysplastic syndrome in one patient in
the palifermin group and one patient in the placebo
group and acute lymphoblastic leukemia in one patient in the palifermin group.

discussion
This study provides evidence that palifermin can
significantly reduce, in a clinically meaningful way,
the duration and incidence of oral mucositis after
intensive chemotherapy and radiotherapy and autologous hematopoietic stem-cell transplantation.
Palifermin consistently decreased the incidence and
duration of severe oral mucositis and its clinical sequelae independently of the measure used, the participating center, the type of underlying disease, and
the number of radiation fractions used. The intensive training of study personnel on the assessment
of oral mucositis enhanced the quality of the data,
and the quantity of missing data was minimal (approximately 3 percent), increasing confidence in the
results. In addition, observer-reported assessments
concurred with patient-reported assessments of the
soreness of the mouth and throat and related functions, including swallowing.
An important finding was that palifermin markedly reduced the incidence of oral mucositis of
WHO grade 4 (20 percent, as compared with 62 percent in the placebo group; P<0.001), the most debilitating form of oral mucositis, in which oral alimentation is impossible. It is consistent with these
findings that the percentage of patients who received total parenteral nutrition, an intervention frequently required for severe oral mucositis,24,25 and
the amount and duration of use of parenteral opioid
analgesics were significantly lower among palifermin recipients than placebo recipients.
Our results are particularly compelling because
of the severity and duration of oral mucositis typically seen in patients with hematologic cancers who
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undergo intensive treatment. Although antibiotics
and topical palliative agents can help manage infections and pain resulting from mild-to-moderate oral
mucositis, none of the growth factors and cytokines unrelated to keratinocyte growth factor tested to date have demonstrated a clear benefit in the
setting of oral mucositis.7,26-30
Severe oral mucositis is associated with an increased risk of blood-borne bacterial infections,
which can be life-threatening.31,32 Our exploratory
analysis of blood-borne infections showed a lower
incidence among patients receiving palifermin than
among those receiving placebo. If confirmed by future investigations, the ability of palifermin therapy
to reduce the breakdown of mucosal barriers could
decrease the complications caused by systemic infection. In turn, reducing the complications of oral
mucositis could decrease the use of parenteral or
transdermal opioid analgesics for mucositis and
parenteral nutrition and reduce the length of hospitalization.
Palifermin is a growth factor. Keratinocyte
growth-factor receptor is not known to be expressed
in hematologic cancers33; nevertheless, the growth
of second tumors that express this receptor is theoretically possible. Evaluation of this risk requires
long-term follow-up, which is ongoing. At 12
months, the progression-free survival rates for palifermin and placebo were nearly identical. In summary, 60 µg of palifermin per kilogram per day was
associated with reductions in the duration and severity of debilitating oral mucositis and related sequelae of high-dose myelosuppressive treatment
with autologous hematopoietic stem-cell support.
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